Synthetic peptides for use in tumor detection
AssigneeAntisoma Limited
InventorAlan W. J. Stuttle
Life of this patent
Estimating the term…
Abstract
Radioactively labelled peptides comprising oligopeptides of from 3 to 10 peptide units and containing the sequence RGD and particularly the oligopeptides RGDSY and RGDFY, are disclosed as in vivo thrombus, tumor or CAM markers for the in vivo diagnosis and detection of thrombi, tumors or CAM in mammals.
Claims4
A method for the in vivo imaging of a tumor having on its surface RGD binding sites comprising the steps of intravenously administering radioactively labelled peptides containing from 3-10 peptide units and having an RGD sequence capable of binding to RGD binding sites on the tumor, allowing for the labelled peptides to bind to the RGD binding sites and for the unbound labelled peptides to systemically clear from the patient, and radiographically detecting the accumulated bound peptides.
A method for the in vivo imaging of a tumor having on its surface RGD binding sites comprising the steps of:
- a) intravenously administering about 100 micrograms of labelled peptides, wherein said peptides contain from 3 to 10 peptide units and wherein 3 of the peptide units are the sequence arginine-glycine-aspartic acid, said sequence having the ability to bind to RGD binding sites on platelets forming the thrombus;
- b) allowing a sufficient period of time for the labelled peptides to bind to the RGD binding sites and for the unbound labelled peptides to systemically clear from the patient and,
- c) detecting the accumulated bound peptides.
Dependencies are inferred from the claim text.